Discussion Several clinical trials in patients with uHCC have demonstrated that dual PD-1 and angiogenesis blockade therapy can achieve a higher tumor response rate than sorafenib with greater tolerability.13–15 However, the prognoses of individual patients vary and are related to patient and tumor characteristics such as liver function, performance status, tumor burden, and macrovascular invasion.16 17 According to recent guidelines, risk stratification and survival prediction in these...
